Maze Therapeutics (MAZE) awards director 36,000 stock options
Rhea-AI Filing Summary
Maze Therapeutics director Sophie Kornowski received a grant of 36,000 stock options on August 13, 2026. The options have an exercise price of $27.665 per share and expire on August 12, 2036. They vest in 36 equal monthly installments beginning September 13, 2026, contingent on her continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Kornowski Sophie
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 36,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 36,000 shares (Direct)
Footnotes (1)
- F1. The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Key Figures
Options Granted: 36,000 shares
Exercise Price: $27.665 per share
Underlying Shares: 36,000 shares
+3 more
6 metrics
Options Granted
36,000 shares
Stock Option (Right to Buy) grant on August 13, 2026
Exercise Price
$27.665 per share
Conversion or exercise price of the granted stock options
Underlying Shares
36,000 shares
Common Stock underlying the stock option grant
Expiration Date
August 12, 2036
Expiration of the stock option grant
Vesting Start Date
September 13, 2026
First 1/36th tranche of the options vests on this date
Post-Transaction Holdings
36,000 derivative securities
Total stock options held following this grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, underlying security
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 27.6650"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option shall vest as to 1/36th of the total award monthly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
underlying security financial
"underlying_security_title: Common Stock"
FAQ
What did MAZE director Sophie Kornowski receive in this Form 4 filing?
She received a grant of 36,000 stock options to purchase Maze Therapeutics common stock. The options represent equity-based compensation and give her the right to buy shares at a fixed exercise price over time.
What is the exercise price of the Maze Therapeutics (MAZE) stock options granted?
The options have an exercise price of $27.665 per share. This is the price at which Sophie Kornowski can purchase Maze Therapeutics common stock when the options vest and are exercised, if she chooses to do so.
When do the newly granted MAZE stock options begin vesting?
The options begin vesting on September 13, 2026. At that time, the first monthly tranche vests, and additional equal tranches vest on each monthly anniversary, subject to her continued service with Maze Therapeutics.
How do the 36,000 Maze Therapeutics (MAZE) options vest over time?
The grant vests as to 1/36th of the total award each month. This means 36 equal monthly installments, starting September 13, 2026, provided Sophie Kornowski continues serving Maze Therapeutics on each vesting date.
When do the Maze Therapeutics (MAZE) stock options granted to Sophie Kornowski expire?
These options expire on August 12, 2036. After this expiration date, any unexercised portion of the 36,000 stock options can no longer be exercised to purchase Maze Therapeutics common stock.
How many Maze Therapeutics (MAZE) derivative securities does Sophie Kornowski hold after this grant?
Following the transaction, she holds 36,000 stock options as reported. These options are derivative securities that represent the right to acquire an equivalent number of Maze Therapeutics common shares upon exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
